The CaMKII K42M and K42R mutations are equivalent in suppressing kinase activity and targeting.
Tullis JE, Rumian NL, Brown CN, Bayer KU. The CaMKII K42M and K42R mutations are equivalent in suppressing kinase activity and targeting. PLoS One. 2020; 15(7):e0236478.